Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies.
Bita Bordbar, Nicaise Tuikue-Ndam, Pascal Bigey...
https://pubmed.ncbi.nlm.nih.gov/22226864/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-10-08
7476
Participants Needed
1
Research Sites
N/A
Total Duration
Malaria is a serious disease caused by parasites spread through mosquito bites, which can be fatal if untreated. Pregnant women, especially those aged 15 to 25, are at higher risk of malaria infection, which can lead to complications like low birth weight and maternal anemia. Researchers are investigating vaccine candidates aimed at preventing pregnancy malaria by studying how antibodies work against the parasite in laboratory tests. This research involves recruiting up to 2492 pregnant women who are malaria-infected from health centers in Mali, West Africa. Blood samples from these participants will be used to test the functional activity of antibodies raised against malaria vaccine candidates in lab assays. The study compares these antibodies to naturally acquired ones to assess their potential in blocking the parasites ability to bind to the placenta. Participants will provide blood samples and may undergo physical exams. Those diagnosed with malaria or anemia will receive treatment. Researchers will measure how well antibodies block the parasites binding to the placental receptor over about one year. The study includes consent for use of samples in future research, and participation may last through the pregnancy period, with ongoing health monitoring and data collection.
CONDITIONS
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
M
Michal Fried, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants provide blood samples for laboratory testing and may have physical exams. Those with malaria or anemia receive treatment as needed.
Regular visits depending on clinical needs
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Bita Bordbar, Nicaise Tuikue-Ndam, Pascal Bigey...
https://pubmed.ncbi.nlm.nih.gov/22226864/Ankur Sharma, Bethany Jenkins, Adovi Akue...
https://pubmed.ncbi.nlm.nih.gov/35290467/M Fried, F Nosten, A Brockman...
https://pubmed.ncbi.nlm.nih.gov/9804416/Michal Fried, Marion Avril, Richa Chaturvedi...
https://pubmed.ncbi.nlm.nih.gov/23208604/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor